#Canada #Victoria #Eupraxia Pharmaceuticals #Alex Rothwell #Bruce Cousins

Eupraxia Pharmaceuticals Announces CFO Transition

Eupraxia Pharmaceuticals Inc., a biotechnology leader in clinical-stage innovations, has officially announced a significant transition within its executive team. Alex Rothwell takes over as the new Chief Financial Officer (CFO), effective immediately, following the retirement of Bruce Cousins, the former CFO. This change marks a strategic move for the company as it continues to progress its innovative treatments in the biopharmaceutical landscape.

Leadership Transition

Bruce Cousins, who has played a pivotal role in the company, particularly during its recent listing on Nasdaq, will remain on board as a consultant to ensure a smooth handover of responsibilities to Rothwell. James Helliwell, the CEO of Eupraxia, expressed gratitude for Cousins’ leadership and essential contributions that have bolstered the company’s foundations for success. Rothwell, who previously served as CFO, is set to bring his comprehensive knowledge of capital markets and in-depth understanding of the company’s vision to his new role.

In Rothwell’s words, “Eupraxia is in an excellent position to create significant value for shareholders, and I’m very focused on helping drive that process.” His commitment reflects the ongoing dedication to enhancing both patient outcomes and shareholder value, particularly through innovative therapeutic candidates like EP-104GI and EP-104IAR.

Expertise and Vision

Rothwell’s extensive experience spans over 25 years in business leadership and capital markets. He began his career in institutional equities in 1995 and held various executive roles in prominent Canadian investment banks. His past tenure as Eupraxia’s CFO from 2018 to 2021 has equipped him with the unique insights needed to push the company's growth initiatives further.

His return comes at a crucial time as Eupraxia aims to develop pioneering treatments focused on unmet medical needs. Currently, EP-104GI is in Phase 1b/2a clinical trials, addressing Eosinophilic Esophagitis. This innovative treatment approach highlights Eupraxia's objective to provide localized medical therapies, therefore enhancing both safety and efficacy.

Future Potential

One of Rothwell’s main priorities is highlighting the potential of EP-104IAR as a leading therapy for knee osteoarthritis, which stands to improve the quality of life for many patients suffering from this condition. He recognized the vast market possibilities that could arise from these innovative treatments, reinforcing Eupraxia's commitment to not only focusing on existing conditions but also expanding applications in other joint areas.

With a dedicated focus on improving drug delivery technologies, such as the proprietary DiffuSphere™, Eupraxia is positioned at the forefront of therapeutic innovation. This platform targets drug delivery directly to intended tissues, enhancing treatment efficacy while minimizing systemic exposure—a critical consideration in today’s pharmacology landscape.

Summary

As Eupraxia Pharmaceuticals embarks on this new chapter with Alex Rothwell at the financial helm, the future appears promising. The insights and strategies he brings to the team are expected to play a vital role in the company’s continued growth. With innovative products under development and a vision for future expansion, Eupraxia is set to contribute significantly to the biotechnology field, addressing critical health challenges. For more updates about Eupraxia and its innovative approaches, visit their official website at Eupraxia Pharmaceuticals.